Abstract: Objective To explore the clinical efficacy of Tongmai Yangxin Pill combined with tirofiban in the treatment of elderly patients with unstable angina pectoris (UAP). Methods From May 2016 to April 2019, a total of 121 patients with UAP treated in Benxi Central Hospital were divided into two groups by using random number table method. The control group was injected with tirofiban hydrochloride and sodium chloride, and the observation group took Tongmai Yangxin Pills on the basis of the control group. After 8 days of treatment, the clinical efficacy, serum indexes, coagulation indexes and the adverse events of the two groups were compared. Results The clinical effective rate in the observation group was higher than that in the control group (P<0.05). There were no significant differences in the serum indicators of galectin-3 (Gal-3), intercellular cell adhesion molecule-1 (ICAM-1), nitric oxide (NO), superoxide dismutase (SOD), D-dimer (D-D), prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) before treatment between the two groups. After treatment, the levels of Gal-3, NO, D-D, PT, TT, APTT and FIB decreased significantly, and the levels of ICAM-1 and SOD increased significantly in the two groups(P<0.05), especially in the observation group. Compared with the control group, the incidence rate of adverse events and the recurernce rate was significantly lower in the observation group (P<0.05). Conclusions Tongmai Yangxin Pill combined with tirofiban hydrochloride in the treatment of UAP can effectively reduce the level of inflammation, improve the blood coagulation function, and have good safety and clinical efficacy.

Key words: Tongmai Yangxin Pill, tirofiban, unstable angina pectoris, efficacy, coagulation function